Compare Lumen Technologies Inc (LUMN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Lumen Technologies Inc trades at $6.29 (market cap $6.58B), while State Street SPDR S&P Biotech ETF trades at $159.12. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.
| LUMN | XBI | |
|---|---|---|
Market Cap | $6.58B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $11.83 | $164.28 |
52-Week Low | $4.31 | $88.79 |
Enterprise Value | $18.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN stock trades at $6.375, down 3.99% today, amid a bearish technical signal and mixed earnings. The company reported a Q2 2026 loss of $0.07 per share, beating estimates, but revenue declined 9.3% year-over-year. Strategic revenues grew 14.1%, highlighting its digital transformation. CEO Kathleen Johnson purchased 100,000 shares on August 6, 2026, signaling insider confidence. Net cash flow was negative $886 million in 2025, though 2026 projections show improvement. The stock faces headwinds from high debt and legacy revenue declines.
LUMN offers a high-risk opportunity with a low P/S ratio of 0.54 and analyst consensus price target of $7.67, implying potential upside. However, persistent net losses, negative ROE of -78.94%, and $17.49 billion in long-term debt pose significant risks. Investors should weigh the digital growth potential against financial instability and cautious analyst sentiment, with 60.71% holding ratings.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
